Hepatitis D – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Hepatitis D – Pipeline Review, H1 2017’, provides an overview of the Hepatitis D pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis D, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hepatitis D

The report reviews pipeline therapeutics for Hepatitis D by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hepatitis D therapeutics and enlists all their major and minor projects

The report assesses Hepatitis D therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hepatitis D

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hepatitis D

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatitis D pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alnylam Pharmaceuticals Inc

Eiger BioPharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Globeimmune Inc

Replicor Inc

Rodos BioTarget GmbH

SomaGenics Inc

Spring Bank Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatitis D - Overview

Hepatitis D - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis D - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis D - Companies Involved in Therapeutics Development

Alnylam Pharmaceuticals Inc

Eiger BioPharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Globeimmune Inc

Replicor Inc

Rodos BioTarget GmbH

SomaGenics Inc

Spring Bank Pharmaceuticals Inc

Hepatitis D - Drug Profiles

ALN-HDV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GI-18000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lonafarnib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myrcludex-B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon alfa-2a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon lambda-1a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBT-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REP-2139 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REP-2165 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RNAi Oligonucleotide for Hepatitis D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-9200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vanitaracin A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatitis D - Dormant Projects

Hepatitis D - Discontinued Products

Hepatitis D - Product Development Milestones

Featured News & Press Releases

May 03, 2017: Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection - LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling

Apr 21, 2017: Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress 2017

Apr 06, 2017: Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting

Apr 04, 2017: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta

Feb 20, 2017: Replicor discloses high rates of HBsAg loss with NAP combination therapy at APASL 2017

Nov 15, 2016: Replicor Discloses Late Breaking HBV and Follow-Up HBV / HDV Clinical Data at AASLD 2016

Nov 14, 2016: Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting

Oct 19, 2016: Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus Infection

Oct 13, 2016: Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting

Sep 07, 2016: Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School

Jul 20, 2016: Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV - 3 Study at National Institutes of Health

Jun 01, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Publication of Myrcludex B Clinical Results in Journal of Hepatology

May 25, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start Of Second Phase 2 Clinical Trial Of Myrcludex B In Chronic Hepatitis B/D Infection

Apr 29, 2016: Interim Results Of A Phase Ib/IIa Study Of The Entry Inhibitor Myrcludex B

Apr 04, 2016: Replicor to Make Three Presentations at EASL 2016

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hepatitis D, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hepatitis D – Pipeline by Alnylam Pharmaceuticals Inc, H1 2017

Hepatitis D – Pipeline by Eiger BioPharmaceuticals Inc, H1 2017

Hepatitis D – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Hepatitis D – Pipeline by Globeimmune Inc, H1 2017

Hepatitis D – Pipeline by Replicor Inc, H1 2017

Hepatitis D – Pipeline by Rodos BioTarget GmbH, H1 2017

Hepatitis D – Pipeline by SomaGenics Inc, H1 2017

Hepatitis D – Pipeline by Spring Bank Pharmaceuticals Inc, H1 2017

Hepatitis D – Dormant Projects, H1 2017

Hepatitis D – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Hepatitis D, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports